Page 401 - Williams Hematology ( PDFDrive )

376 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 377

113. Aoyama K, Koyama M, Matsuoka K, et al: Improved outcome of allogeneic bone mar- 139. Higuchi CM, Thompson JA, Cox T, et al: Lymphokine-activated killer function follow-
row transplantation due to breastfeeding-induced tolerance to maternal antigens. Blood ing autologous bone marrow transplantation for refractory hematological malignan-
113:1829–1833, 2009. cies. Cancer Res 49:5509–5513, 1989.
114. Alici E, Bjorkstrand B, Treschow A, et al: Long-term follow-up of gene-marked CD34+ 140. Linn YC, Niam M, Chu S, et al: The anti-tumour activity of allogeneic cytokine-induced
cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther killer cells in patients who relapse after allogeneic transplant for haematological malig-
14:227–232, 2007. nancies. Bone Marrow Transplant 47:957–966, 2012.
115. Brenner MK, Rill DR, Moen RC, et al: Gene-marking to trace origin of relapse after 141. Laport GG, Sheehan K, Baker J, et al: Adoptive immunotherapy with cytokine-induced
autologous bone-marrow transplantation. Lancet 341:85–86, 1993. killer cells for patients with relapsed hematologic malignancies after allogeneic hemato-
116. Kasamon YL, Jones RJ, Gocke CD, et al: Extended follow-up of autologous bone poietic cell transplantation. Biol Blood Marrow Transplant 17:1679–1687, 2011.
marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for 142. Venstrom JM, Pittari G, Gooley TA, et al: HLA-C-dependent prevention of leukemia
indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transplant relapse by donor activating KIR2DS1. N Engl J Med 367:805–816, 2012.
17:365–373, 2011. 143. Ringden O, Labopin M, Gorin NC, et al: Is there a graft-versus-leukaemia effect in the
117. Bartee E, Chan WM, Moreb JS, et al: Selective purging of human multiple myeloma absence of graft-versus-host disease in patients undergoing bone marrow transplanta-
cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. tion for acute leukaemia? Br J Haematol 111:1130–1137, 2000.
Biol Blood Marrow Transplant 18:1540–1551, 2012. 144. Edinger M, Hoffmann P, Ermann J, et al: CD4+CD25+ regulatory T cells preserve
118. Pettengell R, Schmitz N, Gisselbrecht C, et al: Rituximab purging and/or maintenance graft-versus-tumor activity while inhibiting graft-versus-host disease after bone mar-
in patients undergoing autologous transplantation for relapsed follicular lymphoma: A row transplantation. Nat Med 9:1144–1150, 2003.
prospective randomized trial from the lymphoma working party of the European group 145. Di Ianni M, Falzetti F, Carotti A, et al: Tregs prevent GVHD and promote immune
for blood and marrow transplantation. J Clin Oncol 31:1624–1630, 2013. reconstitution in HLA-haplo-identical transplantation. Blood 117:3921–3928, 2011.
119. Yahng SA, Yoon JH, Shin SH, et al: Influence of ex vivo purging with CliniMACS 146. Martelli MF, Di Ianni M, Ruggeri L, et al: HLA-haplo-identical transplantation with
CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodg- regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia
kin lymphoma. Br J Haematol 164:555–564, 2014. relapse. Blood 124:638–644, 2014.
120. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed 147. Clift RA, Buckner CD, Appelbaum FR, et al: Long-term follow-Up of a randomized
by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J trial of two irradiation regimens for patients receiving allogeneic marrow transplants
Med 325:1525–1533, 1991. during first remission of acute myeloid leukemia. Blood 92:1455–1456, 1998.
121. van Heeckeren WJ, Vollweiler J, Fu P, et al: Randomised comparison of two B-cell purg- 148. Faraci M, Barra S, Cohen A, et al: Very late nonfatal consequences of fractionated TBI
ing protocols for patients with B-cell non-Hodgkin lymphoma: In vivo purging with in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 63:1568–
rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J 1575, 2005.
Haematol 132:42–55, 2006. 149. Thomas O, Mahe M, Campion L, et al: Long-term complications of total body irradia-
122. Stewart AK, Vescio R, Schiller G, et al: Purging of autologous peripheral-blood stem tion in adults. Int J Radiat Oncol Biol Phys 49:125–131, 2001.
cells using CD34 selection does not improve overall or progression-free survival after 150. Kolb HJ, Socie G, Duell T, et al: Malignant neoplasms in long-term survivors of bone
high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized marrow transplantation. Late Effects Working Party of the European Cooperative
controlled trial. J Clin Oncol 19:3771–3779, 2001. Group for Blood and Marrow Transplantation and the European Late Effect Project
123. Holmberg LA, Boeckh M, Hooper H, et al: Increased incidence of cytomegalovirus dis- Group. Ann Intern Med 131:738–744, 1999.
ease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 151. Cosset JM, Baume D, Pico JL, et al: Single dose versus hyperfractionated total body irra-
94:4029–4035, 1999. diation before allogeneic bone marrow transplantation: A non-randomized compara-
124. Crippa F, Holmberg L, Carter RA, et al: Infectious complications after autologous tive study of 54 patients at the Institut Gustave-Roussy. Radiother Oncol 15:151–160,
CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Trans- 1989.
plant 8:281–289, 2002. 152. Shank B, O’Reilly RJ, Cunningham I, et al: Total body irradiation for bone marrow
125. Kernan NA, Flomenberg N, Dupont B, et al: Graft rejection in recipients of T-cell- transplantation: The Memorial Sloan-Kettering Cancer Center experience. Radiother
depleted HLA-nonidentical marrow transplants for leukemia. Identification of host- Oncol 18 (Suppl 1):68–81, 1990.
derived antidonor allocytotoxic T lymphocytes. Transplantation 43:842–847, 1987. 153. Marks DI, Forman SJ, Blume KG, et al: A comparison of cyclophosphamide and total
126. Kernan NA, Bordignon C, Heller G, et al: Graft failure after T-cell-depleted human body irradiation with etoposide and total body irradiation as conditioning regimens
leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or
and results of secondary transplants. Blood 74:2227–2236, 1989. second complete remission. Biol Blood Marrow Transplant 12:438–453, 2006.
127. Fefer A, Cheever MA, Thomas ED, et al: Bone marrow transplantation for refractory 154. Jamieson CH, Amylon MD, Wong RM, et al: Allogeneic hematopoietic cell transplan-
acute leukemia in 34 patients with identical twins. Blood 57:421–430, 1981. tation for patients with high-risk acute lymphoblastic leukemia in first or second com-
128. Gale RP, Horowitz MM, Ash RC, et al: Identical-twin bone marrow transplants for leu- plete remission using fractionated total-body irradiation and high-dose etoposide: A
kemia. Ann Intern Med 120:646–652, 1994. 15-year experience. Exp Hematol 31:981–986, 2003.
129. Martin PJ, Clift RA, Fisher LD, et al: HLA-identical marrow transplantation during 155. Pagel JM, Gooley TA, Rajendran J, et al: Allogeneic hematopoietic cell transplantation
accelerated-phase chronic myelogenous leukemia: Analysis of survival and remission after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total
duration. Blood 72:1978–1984, 1988. body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk
130. Kolb HJ, Mittermuller J, Clemm C, et al: Donor leukocyte transfusions for treatment myelodysplastic syndrome. Blood 114:5444–5453, 2009.
of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 156. Gopal AK, Guthrie KA, Rajendran J, et al: (9)(0)Y-Ibritumomab tiuxetan, fludarabine,
76:2462–2465, 1990. and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients
131. Drobyski WR, Keever CA, Roth MS, et al: Salvage immunotherapy using donor leu- with persistent high-risk B-cell lymphoma. Blood 118:1132–1139, 2011.
kocyte infusions as treatment for relapsed chronic myelogenous leukemia after alloge- 157. Gopal AK, Gooley TA, Rajendran JG, et al: Myeloablative I-131-tositumomab with
neic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood escalating doses of fludarabine and autologous hematopoietic transplantation for adults
82:2310–2318, 1993. age ≥ 60 years with B cell lymphoma. Biol Blood Marrow Transplant 20:770–775, 2014.
132. Dazzi F, Szydlo RM, Cross NC, et al: Durability of responses following donor lympho- 158. Mawad R, Gooley TA, Rajendran JG, et al: Radiolabeled anti-CD45 antibody with
cyte infusions for patients who relapse after allogeneic stem cell transplantation for reduced-intensity conditioning and allogeneic transplantation for younger patients
chronic myeloid leukemia. Blood 96:2712–2716, 2000. with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Mar-
133. Ruggeri L, Mancusi A, Capanni M, et al: Donor natural killer cell allorecognition of row Transplant 20:1363–1368, 2014.
missing self in haplo-identical hematopoietic transplantation for acute myeloid leuke- 159. Nakamae H, Wilbur DS, Hamlin DK, et al: Biodistributions, myelosuppression, and
mia: Challenging its predictive value. Blood 110:433–440, 2007. toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting
134. Bellucci R, Alyea EP, Chiaretti S, et al: Graft-versus-tumor response in patients with radionuclides bismuth-213 or astatine-211. Cancer Res 69:2408–2415, 2009.
multiple myeloma is associated with antibody response to BCMA, a plasma-cell mem- 160. Park SI, Shenoi J, Pagel JM, et al: Conventional and pretargeted radioimmunotherapy
brane receptor. Blood 105:3945–3950, 2005. using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: A
135. Faber LM, van der Hoeven J, Goulmy E, et al: Recognition of clonogenic leukemic preclinical model toward optimal consolidation therapy to eradicate minimal residual
cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or disease. Blood 116:4231–4239, 2010.
CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 161. Pagel JM, Kenoyer AL, Back T, et al: Anti-CD45 pretargeted radioimmunotherapy
96:877–883, 1995. using bismuth-213: High rates of complete remission and long-term survival in a
136. Bonnet D, Warren EH, Greenberg PD, et al: CD8(+) minor histocompatibility mouse myeloid leukemia xenograft model. Blood 118:703–711, 2011.
antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leuke- 162. Orozco JJ, Back T, Kenoyer A, et al: Anti-CD45 radioimmunotherapy using (211)At
mia stem cells. Proc Natl Acad Sci U S A 96:8639–8644, 1999. with bone marrow transplantation prolongs survival in a disseminated murine leuke-
137. Scheibenbogen C, Letsch A, Thiel E, et al: CD8 T-cell responses to Wilms tumor mia model. Blood 121:3759–3767, 2013.
gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 163. Pecego R, Hill R, Appelbaum FR, et al: Interstitial pneumonitis following autologous
100:2132–2137, 2002. bone marrow transplantation. Transplantation 42:515–517, 1986.
138. Delmon L, Ythier A, Moingeon P, et al: Characterization of antileukemia cells’ cytotoxic 164. Law LY, Horning SJ, Wong RM, et al: High-dose carmustine, etoposide, and cyclophos-
effector function. Implications for monitoring natural killer responses following alloge- phamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin
neic bone marrow transplantation. Transplantation 42:252–256, 1986. lymphoma. Biol Blood Marrow Transplant 12:703–711, 2006.

Kaushansky_chapter 23_p0353-0382.indd 376 9/19/15 12:47 AM